Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib | BioMed Central Journal of Hematology Oncology Open Access Review The occurrence and management of fluid retention associated with TKI therapy in CML with a focus on dasatinib David Masiello Gerry Gorospe III and Allen S Yang Address Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases University of Southern California Medical Center 1441 Eastlake Ave Suite 7317 Los Angeles CA 90033 USA Email David Masiello - masiello@ Gerry Gorospe - gorospe@ Allen S Yang - allenyan@ Corresponding author Published 12 November 2009 Received 28 August 2009 __ _ AAQ - . A I IO - - O-Í-I-I 1 At Accepted 12 November 2009 Journal of Hematology Oncology 2009 2 46 doi 1756-8722-2-46 This article is available from http content 2 1 46 2009 Masiello et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract__ Tyrosine kinase inhibitors TKIs like dasatinib and nilotinib are indicated as second-line treatment for chronic myeloid leukemia resistant or intolerant to the current first-line TKI imatinib. These are agents are well tolerated but potent and as such should be monitored for potentially serious side-effects like fluid retention and pleural effusions. Here we present key clinical trial data and safety considerations for all FDA approved TKIs in context for effective management of fluid retention and pleural effusions. Altering the dasatinib regimen from 70 mg twice daily to 100 mg daily reduces the risk of pleural effusion for patients taking dasatinib. Should pleural effusion develop dasatinib should be interrupted until the condition resolves. Patients with a history of pleural .
